quinidine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
2346 56-54-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • quincardine
  • quinidine polygalacturonate
  • quinidine sulfate dihydrate
  • quinidine
  • quinidine sulfate
  • quinidine gluconate
  • chinidin
  • conchinin
  • conchinine
  • conquinine
  • quindine
  • pitayine
  • beta-Quinidine
  • quinidine hydrochloride monohydrate
  • quinidine hydrochloride
  • quinidine HCl
An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.
  • Molecular weight: 324.42
  • Formula: C20H24N2O2
  • CLOGP: 2.79
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 45.59
  • ALOGS: -2.99
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.20 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 11.10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 18 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 30.82 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 80 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 2.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.26 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 6.60 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.018 Moderate 0.74
caco2-efflux Caco-2 efflux ratio (BA/AB) 3.436 Moderate 0.74
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 18.408 10^-6 cm/s Moderate 0.74
dh-clint Dog hepatocyte intrinsic clearance 8.204 uL/min/10^6 cells Moderate 0.74
dppb Dog plasma protein binding (% unbound) 22.830 % Moderate 0.74
fcs-ppb Fetal calf serum protein binding (% unbound) 46.380 % Moderate 0.74
herg hERG pIC50 5.636 pIC50 Moderate 0.74
hh-clint Human hepatocyte intrinsic clearance 4.198 uL/min/10^6 cells Moderate 0.74
hlm-clint Human liver microsomal intrinsic clearance 32.961 uL/min/mg protein Moderate 0.74
hppb Human plasma protein binding (% unbound) 23.480 % Moderate 0.74
kinase-safety-class ACVR2B,AXL,CAMK2D,EIF2AK3,GRK2,ITK,PDK1,PDK2,PDK4,PRKDC 10
kinase-selectivity-class AXL,CAMK2D,CDK9,EIF2AK3,MAP2K6 5
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 12.331 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 6.934 Moderate 0.74
mh-clint Mouse hepatocyte intrinsic clearance 75.336 Moderate 0.74
mppb Mouse plasma protein binding (% unbound) 22.340 Moderate 0.74
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 31.189 Moderate 0.74
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 High 1
pppb Pig plasma protein binding (% unbound) 38.630 % Moderate 0.74
rat-kpuu-brain Rat brain Kpuu 0.031 % High 1
rh-clint Rat hepatocyte intrinsic clearance 60.395 uL/min/10^6 cells Moderate 0.74
rh-fuinc Rat hepatocyte fraction unbound in incubation 66.510 % Moderate 0.74
rppb Rat plasma protein binding (% unbound) 29.280 % Moderate 0.74
solubility-dd Solubility at pH 7.4 in DMSO 849.180 uM Moderate 0.74

Approvals:

DateAgencyCompanyOrphan
July 12, 1950 FDA LILLY

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Gliosis 98.55 50.44 14 820 481 90627132
Polyserositis 94.25 50.44 14 820 659 90626954
Pouchitis 94.17 50.44 14 820 663 90626950
Premature menopause 84.73 50.44 14 820 1315 90626298
Ovarian failure 81.77 50.44 14 820 1629 90625984
Somatic symptom disorder 77.58 50.44 15 819 3426 90624187
Antiphospholipid syndrome 77.22 50.44 14 820 2260 90625353
Venous thrombosis limb 71.35 50.44 14 820 3448 90624165
Cardiac tamponade 64.55 50.44 14 820 5618 90621995

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 117.26 40.81 67 275 630130 41990863
Electrocardiogram QT prolonged 44.39 40.81 16 326 47929 42573064

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Gliosis 90.50 38.25 14 1206 718 110587361
Ovarian failure 86.48 38.25 14 1206 962 110587117
Polyserositis 85.67 38.25 14 1206 1020 110587059
Premature menopause 85.56 38.25 14 1206 1028 110587051
Pouchitis 81.46 38.25 14 1206 1383 110586696
Somatic symptom disorder 76.10 38.25 15 1205 3144 110584935
Antiphospholipid syndrome 73.20 38.25 14 1206 2509 110585570
Electrocardiogram QT prolonged 68.06 38.25 30 1190 108930 110479149
Drug ineffective 65.06 38.25 81 1139 1520459 109067620
Venous thrombosis limb 62.93 38.25 14 1206 5251 110582828
Cardiac tamponade 52.29 38.25 14 1206 11293 110576786
Proctectomy 45.58 38.25 7 1213 341 110587738
Lupus-like syndrome 41.69 38.25 16 1204 40776 110547303
Intervertebral disc protrusion 39.93 38.25 14 1206 27684 110560395

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C01BA01 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
ANTIARRHYTHMICS, CLASS I AND III
Antiarrhythmics, class Ia
ATC C01BA51 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
ANTIARRHYTHMICS, CLASS I AND III
Antiarrhythmics, class Ia
ATC C01BA71 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
ANTIARRHYTHMICS, CLASS I AND III
Antiarrhythmics, class Ia
FDA EPC N0000175426 Antiarrhythmic
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000962 Antimalarials
MeSH PA D000977 Antiparasitic Agents
MeSH PA D000981 Antiprotozoal Agents
MeSH PA D000317 Adrenergic alpha-Antagonists
MeSH PA D000889 Anti-Arrhythmia Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018663 Adrenergic Agents
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018727 Muscarinic Antagonists
MeSH PA D026941 Sodium Channel Blockers
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D061567 Voltage-Gated Sodium Channel Blockers
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D065690 Cytochrome P-450 CYP2D6 Inhibitors
FDA EPC N0000182135 Cytochrome P450 2D6 Inhibitor
FDA MoA N0000182137 Cytochrome P450 2D6 Inhibitors
CHEBI has role CHEBI:176497 geroprotector
CHEBI has role CHEBI:37890 ฮฑ-adrenergic antagonist
CHEBI has role CHEBI:38068 antimalarial
CHEBI has role CHEBI:38070 anti-arrhythmia drug
CHEBI has role CHEBI:38633 sodium channel blocker
CHEBI has role CHEBI:48876 muscarinic antagonist
CHEBI has role CHEBI:50183 P450 inhibitor
CHEBI has role CHEBI:50509 potassium channel blocker
CHEBI has role CHEBI:77748 EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor
CHEBI has role CHEBI:77781 EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor
CHEBI has role CHEBI:88188 drug allergen

Related Drugs by ATC class:

C01BA Antiarrhythmics, class Ia 7 drugs
ajmalinedisopyramidehydroquinidinelorajmineprajmaliumprocainamidesparteine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Atrial fibrillation indication 49436004 DOID:0060224
Malaria indication 61462000 DOID:12365
Pseudobulbar affect indication 432776007
Life-Threatening Ventricular Tachycardia indication
Cardioversion of Atrial Fibrillation indication
Psoriasis contraindication 9014002 DOID:8893
Poisoning by digitalis glycoside contraindication 12876009
Complete atrioventricular block contraindication 27885002
Torsades de pointes contraindication 31722008
Hypokalemia contraindication 43339004
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Left ventricular hypertrophy contraindication 55827005
Poisoning by quinidine contraindication 59826007
Left bundle branch block contraindication 63467002
Left heart failure contraindication 85232009
Pulmonary emphysema contraindication 87433001
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Anemia due to enzyme deficiency contraindication 111577008
Prolonged QT interval contraindication 111975006
Hypomagnesemia contraindication 190855004
Partial atrioventricular block contraindication 195039008
Disease of liver contraindication 235856003 DOID:409
Esophageal dysmotility contraindication 266434009 DOID:9192
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Congenital long QT syndrome contraindication 442917000
Non-specific intraventricular conduction delay contraindication 698252002
Digitalis Toxicity with AV Conduction Defects contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.44 acidic
pKa2 8.02 Basic
pKa3 4.1 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
20MG;10MG NUEDEXTA OTSUKA AMERICA PHARM N021879 Oct. 29, 2010 RX CAPSULE ORAL 7659282 Aug. 13, 2026 TREATMENT OF PSEUDOBULBAR AFFECT

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel BLOCKER IC50 5.49 CHEMBL CHEMBL
Sodium channel protein type 5 subunit alpha Ion channel BLOCKER IC50 5.16 CHEMBL CHEMBL
Cytochrome P450 2D6 Enzyme INHIBITOR Ki 7.92 SCIENTIFIC LITERATURE DRUG LABEL
Sodium channel subunit beta-3 Ion channel WOMBAT-PK
Sodium channel subunit beta-4 Ion channel WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 6.49 CHEMBL
Multidrug resistance protein 1 Transporter Ki 5.59 CHEMBL
Muscarinic acetylcholine receptor M2 GPCR Ki 8.13 PDSP
Cholinesterase Enzyme IC50 5.91 CHEMBL
Potassium voltage-gated channel subfamily A member 5 Ion channel BLOCKER Kd 5.20 IUPHAR
Potassium channel subfamily T member 1 Ion channel IC50 4.80 CHEMBL
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Ion channel IC50 4.11 WOMBAT-PK
Potassium voltage-gated channel subfamily A member 7 Ion channel BLOCKER Kd 4.80 IUPHAR
Solute carrier family 22 member 2 Transporter IC50 4.06 WOMBAT-PK
Multidrug and toxin extrusion protein 1 Transporter IC50 4.95 CHEMBL
Equilibrative nucleoside transporter 4 Transporter INHIBITOR Ki 4.60 IUPHAR
Potassium voltage-gated channel subfamily H member 1 Ion channel BLOCKER IC50 5.80 IUPHAR
Sodium channel subunit beta-1 Ion channel WOMBAT-PK
Sodium channel subunit beta-2 Ion channel WOMBAT-PK
Sodium channel protein type 5 subunit alpha Ion channel BLOCKER IC50 5 IUPHAR
Cholinesterase Enzyme IC50 5.13 CHEMBL
Potassium voltage-gated channel subfamily D member 2 Ion channel IC50 5.66 CHEMBL
Potassium channel subfamily T member 1 Ion channel BLOCKER IC50 4 IUPHAR

External reference:

IDSource
4017419 VUID
N0000179295 NUI
D00642 KEGG_DRUG
27555-34-6 SECONDARY_CAS_RN
6591-63-5 SECONDARY_CAS_RN
7054-25-3 SECONDARY_CAS_RN
4017417 VANDF
4017418 VANDF
4017419 VANDF
4019925 VANDF
C0034414 UMLSCUI
CHEBI:28593 CHEBI
QDN PDB_CHEM_ID
CHEMBL1294 ChEMBL_ID
CHEMBL1201486 ChEMBL_ID
CHEMBL3707183 ChEMBL_ID
DB00908 DRUGBANK_ID
CHEMBL1200437 ChEMBL_ID
D011802 MESH_DESCRIPTOR_UI
441074 PUBCHEM_CID
2342 IUPHAR_LIGAND_ID
C047144 MESH_SUPPLEMENTAL_RECORD_UI
C016713 MESH_SUPPLEMENTAL_RECORD_UI
6151-40-2 SECONDARY_CAS_RN
1668-99-1 SECONDARY_CAS_RN
ITX08688JL UNII
35220 RXNORM
2389 MMSL
2395 MMSL
5402 MMSL
5403 MMSL
5404 MMSL
72295 MMSL
d00020 MMSL
000618 NDDF
000619 NDDF
000620 NDDF
000621 NDDF
004377 NDDF
1217203007 SNOMEDCT_US
31306009 SNOMEDCT_US
372697008 SNOMEDCT_US
5907009 SNOMEDCT_US
77632008 SNOMEDCT_US
82230005 SNOMEDCT_US
CHEMBL2165709 ChEMBL_ID
ITX08688JL INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dextromethorphan hydrobromide and quinidine sulfate HUMAN PRESCRIPTION DRUG LABEL 2 31722-693 CAPSULE 10 mg ORAL ANDA 28 sections
QUINIDINE SULFATE HUMAN PRESCRIPTION DRUG LABEL 1 42806-512 TABLET 300 mg ORAL ANDA 20 sections
QUINIDINE SULFATE HUMAN PRESCRIPTION DRUG LABEL 1 42806-513 TABLET 200 mg ORAL ANDA 20 sections
Quinidine Gluconate HUMAN PRESCRIPTION DRUG LABEL 1 51407-288 TABLET, EXTENDED RELEASE 324 mg ORAL ANDA 26 sections
Quinidine Gluconate HUMAN PRESCRIPTION DRUG LABEL 1 53489-141 TABLET, EXTENDED RELEASE 324 mg ORAL ANDA 26 sections
Nuedexta HUMAN PRESCRIPTION DRUG LABEL 2 59148-053 CAPSULE, GELATIN COATED 10 mg ORAL NDA 27 sections
NUEDEXTA HUMAN PRESCRIPTION DRUG LABEL 2 64597-301 CAPSULE, GELATIN COATED 10 mg ORAL NDA 27 sections
NUEDEXTA HUMAN PRESCRIPTION DRUG LABEL 2 64597-301 CAPSULE, GELATIN COATED 10 mg ORAL NDA 27 sections
Quinidine Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 68151-1991 TABLET 200 mg ORAL ANDA 13 sections
Quinidine Gluconate HUMAN PRESCRIPTION DRUG LABEL 1 68151-2701 TABLET, EXTENDED RELEASE 324 mg ORAL ANDA 25 sections
Quinidine gluconate Human Prescription Drug Label 1 71930-016 TABLET, EXTENDED RELEASE 324 mg ORAL ANDA 13 sections